In the rapidly evolving field of Cell and Gene Therapy (CGT), producing Adeno-Associated Virus (AAV) vectors efficiently remains a significant industry challenge. Traditional transfection reagents often come with drawbacks, including high costs and scalability issues during large-scale manufacturing. YEASEN Bio’s PEI AAV transfection reagents overcome these hurdles by leveraging cutting-edge technology to deliver innovative, cost-effective solutions.
Designed specifically for large-scale recombinant AAV production in suspension 293 cell lines, YEASEN Bio’s proprietary PEI AAV transfection reagent reduces reagent usage by 50% (plasmid:reagent ratio = 1:0.5) while maintaining an impressive viral yield of E12 VG/mL. Compared to Brand P transfection reagents, it excels in both viral titer and full/empty capsid ratio, offering a superior option for AAV packaging.
Core Advantages of YEASEN Bio’s PEI AAV Transfection Reagent
1. Halved Reagent Usage with Cost Efficiency
Engineered for large-scale AAV production in suspension 293 cell lines, this reagent cuts consumption by half (plasmid:reagent ratio = 1:0.5) without sacrificing viral yield (E12 VG/mL). It also improves the full/empty capsid ratio, simplifying downstream purification by reducing impurities. Even with 50% less reagent in 293F suspension cells, the viral titer remains consistently high, making it a cost-effective solution for manufacturers.
2. High-Efficiency Transfection & Broad Serotype Compatibility
This reagent outperforms traditional PEI and competing products in transfection efficiency. It supports robust AAV production across multiple serotypes (AAV2, AAV5, AAV6, AAV8, AAV9) in 293F suspension cells, delivering significantly higher viral yields. With an optimized complex volume as low as 1% of the total volume, it streamlines large-scale manufacturing by overcoming volumetric limitations found in conventional processes.
3. GMP Compliance & DMF Filing for Regulatory Success
Manufactured under stringent GMP guidelines and ISO 13485-certified quality systems, this reagent guarantees batch-to-batch consistency. YEASEN Bio has achieved the following milestones:
- Completed three GMP-grade production batches
- Secured a Drug Master File (DMF)
- Assisted multiple clients in successful Investigational New Drug (IND) application submissions
- Provided audit-ready documentation and regulatory expertise to accelerate CGT project timelines
 |
 |
Figure 1. PEI AAV enables efficient viral vector production with reduced PEI and plasmid inputs. AAV9 was produced in suspension 293F cells, harvested 72 hours post-transfection.
4. Robust Proprietary R&D and Premium Manufacturing Ecosystem
Core R&D Competencies: From Foundational Innovation to Global Technological Breakthroughs
YEASEN Bio’s elite R&D team, composed of world-class experts in polymer chemistry, genetic engineering, and AI-driven computational biology, drives innovation through two proprietary technology platforms:
a) AI-Driven Molecular Design Platform
- Utilizes AI-powered molecular dynamics simulations and high-throughput virtual screening to analyze PEI molecule structure-function relationships, quickly identifying optimal modification sites.
- Example: By simulating PEI-cell membrane interactions, the platform optimized cationic density and hydrophobic moiety ratios, reducing cytotoxicity by 30% and boosting transfection efficiency by 2.5x.
b) High-Throughput Bio-Validation Platform
- Combines automated cell culture systems with flow cytometry to evaluate transfection efficiency and cytotoxicity in parallel, speeding up the transition from lab to industry.
- Milestone: Screened over 1,000 PEI derivatives to select top candidates with compatibility across multiple serotypes (AAV2/5/6/8/9) and completed three GMP-grade production batches.
Figure 2. Screening of PEI-Modified Molecules
Smart Manufacturing: Globally Compliant GMP Systems
a) Regulatory-Compliant GMP Facilities
-
GMP production base in Wuhan:
- Total area: Over 10,000 m² | Annual capacity: Over 10,000 liters
- Fully compliant with cGMP and ISO 13485 standards
- Modular design supports flexible scale-up and tailored production, meeting audit requirements for US and China regulatory submissions.
b) Rigorous Quality Control Framework
- A three-tier quality control system (raw materials → process → finished products) ensures consistent quality across batches.
-
Process Analytical Technology (PAT) monitors key parameters:
- PEI molecular weight distribution
- Charge density
- PDI (polydispersity index)
Figure 3. ISO 13485-Certified Production Facility
Product Information
|
Product Name |
Product Number |
Product Specifications |
|
40823ES03 / 40823ES10 / 40823ES60 |
1 mL / 10 mL / 100 mL |
|
|
40824ES10 / 40824ES60 / 40824ES80 |
10 mL / 100 mL / 1 L |